Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment

Hodgkin Lymphoma

“…Carl Sternberg (from Austria) provided the first detailed description of these cells in 1898, and in 1902 Dorothy Reed Mendenhall (from the USA) independently described these cells. In nodular lymphocyte predominant Hodgkin lymphoma, "popcorn" cells (LP cells, formerly known as lymphohistiocytic cells or L&H cells) are observed [2]. These are large cells with a hyperlobulated nucleus.…”

“…This disease is a predominantly male disease, with a 3:1 male-to-female ratio in Caucasians and a 1.2:1 ratio in African individuals. In adults, the median age of onset is 30À35 years [2]. Most patients present with localized peripheral lymphadenopathy that develops slowly and is responsive to therapy.…”

An update on emerging drugs for Hodgkin lymphoma

“…Virtually, all HRS cells abundantly express the CD30 antigen, which is therefore routinely determined by the pathologist if HL is suspected. In addition to classical HL, 5% of patients with HL present with a different histology and clinical course and are classified as nodular lymphocyte predominant HL [4]. This review focuses on classical HL only.…”

Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival

“…[1] Traditionally, patients with NLPHL present with localized, early-stage peripheral lymphadenopathy, and are less likely to present with “B” symptoms, bulky disease, or mediastinal involvement. [2-6] Thus the behavior of this disease entity contrasts favorably to classical HL (cHL), and its clinical behavior is more comparable to that of an indolent non-Hodgkin’s lymphoma. [7-12] A retrospective matched-pair analysis from the German Hodgkin Study Group (GHSG) of 394 patients with NLPHL (compared to 7,904 patients with cHL) confirmed these findings and validated the improved prognosis (tumor control and overall survival) of this disease entity.…”